35 results about "Atrioventricular block" patented technology

In a system that includes a ventricular pacemaker, the system adjusts an atrioventricular delay to synchronize the onset of isovolumetric contraction with the completion of ventricular filling. The system adjusts the atrioventricular delay as a function of electrical and pressure data from the heart. The system further adjusts the atrioventricular delay as a function of measurements of the time interval between a cardiac occurrence such as a ventricular pace and the completion of ventricular filling. The system may also adjust the atrioventricular delay as a function of the heart rate.

A device including circuits able to control the switching of a AAI mode in a DDD mode, and conversely the return of DDD mode to AAI mode, according to predetermined criteria of detection of atrio-ventricular block (AVB) of the first, second, or third degree and of ventricular pause. The device includes moreover circuits for detecting state, able to diagnose at least a specific temporary state of the patient, in particular a state of effort or sleep, and the circuits for mode switching operate in response to these circuits for detecting state to modify selectively, for the length of time when the aforementioned state is diagnosed, the criteria of switching from AAI mode towards DDD mode and / or the criteria of return to AAI mode, and / or the criteria of final commutation in DDD mode.

The present invention relates to a preventive and / or therapeutic agent for hyperkalemia, and a potassium excretion promoter containing EP4 agonist. Since EP4 agonist promotes potassium excretion, it is useful as a preventive and / or therapeutic agent for hyperkalemia. In addition, if selective EP4 agonist uses, it is a preventive and / or therapeutic agent for hyperkalemia without side effects. Further, if EP4 agonist is used, it is useful as improving agent for various symptoms (e.g. paresthesia, error of perception, weakness, myoparalysis, nausea, vomit, abdominal pain, diarrhea, arrhythmia, atrioventricular block, ventricular fibrillation, atrial fibrillation, cardiac arrest, asphyxia and / or dyspnoea etc.).

An active implantable medical device including circuits for calculating an atrio ventricular delay (AVD) period. The device is able to detect the atrial and ventricular events; calculate an AVD and to start the AVD on detection of a spontaneous or paced atrial event. The device is able to deliver a low energy ventricular stimulation pulse at the expiration of the AVD in the absence of a detected spontaneous ventricular event. To calculate the AVD, the device uses an acceleration sensor to deliver an endocardiac acceleration (EA) signal representative of the movements produced by the contractions of the atrial cavity; and analyzes the EA signal to identify and isolate in the EA signal a component corresponding to the fourth peak of endocardiac acceleration (PEA4) associated to the atrial activity, and to calculate the AVD based on a parameter of this component.

The present invention discloses a method for eliminating atrial far-field signals in ventricular channels for an implantable cardiac pacemaker. The method includes the following steps that: 1) if atrial and ventricular sensing events occur simultaneously in an atrial and ventricular sensing window in a VA interval, the following processing is carried out: 1, if a VV interval is larger than 300ms, current ventricular sensing is ignored, a 100ms safety AV interval is enabled, and 2, if the VV interval is smaller than or equal to 300ms, atrial and ventricular sensing is caused by T waves, and atrial sensing and ventricular sensing are simultaneously ignored, and a 100ms atrial and ventricular absolute refractory period is enabled; and 2) in the AV interval of the atrial sensing, a 50ms long-field signal detection window is enabled, if a ventricular sensing event is detected in the window, and current ventricular sensing is ignored, and a 100ms safety AV interval is enabled, ventricular safety pacing is realized at the tail end of a ventricular sensing window. With the method of the invention adopted, the suppression of ventricular pacing pulses caused by cross sensing can be avoided, and therefore, the life of a patient having atrioventricular block can be effectively protected.

The invention provides a seamless aortic valve replacement device implanted under surgical orthophoria. The seamless aortic valve replacement device is characterized by comprising a metal support, a terylene ring, a joint tab and an artificial valve, wherein the metal support comprises a support inflow end, an oar-shaped support part and a support outflow end, wherein the oar-shaped support part is connected with the support inflow end and the support outflow end respectively; the terylene ring is fixed at the support inflow end; the joint tab is fixed at the oar-shaped support part; and a near end of the artificial valve is fixed on the inner side of the terylene ring, and a far end of the artificial valve is fixed on the inner side of the joint tab. According to the seamless aortic valve replacement device, the whole height of the device can be effectively reduced; and at the same time, large-area circular terylene is seamed at the support inflow end, fixation of the whole device in a left ventricle outflow tract is enhanced, and integrated expansion is facilitated, so that the inflow end and the outflow end of the metal support can be well anchored an aorta wall, and the occurrence rate of complication of valve displacement, perivalvular leakage, atrioventricular block and the like is decreased.

The invention discloses a traditional Chinese medicine composition used for treating atrioventricular block, which comprises the following raw materials by weight part: 15-20 parts of cassia twig, 18-25 parts of white peony root, 10-20 parts of raw licorice; 2-10 parts of Jujube, 6-8 parts of ginger, 4-10 parts of pseudo-ginseng, 3-12 parts of Radix Astragali and 3-5 parts of Radix Codonopsis. The traditional Chinese medicine composition has the advantages of good treatment effect and no toxic and side effect on liver and kidney.

A method of increasing the velocity of AV conduction in a mammal that may be in heart block or at risk of heart block by causing, in an AV node and / or His bundle having less than normal conduction speed, the expression of a sodium channel or gap junction protein, such as the SkM-1 channel, Cx43 or Cx32, so as to increase the velocity of conduction by the AV node.

The invention discloses a traditional Chinese medicine composition for treating bundle branch block and related heart diseases. The traditional Chinese medicine is made by combining Chinese herbal formulas of monkshood, dried radix rehmanniae, polygonum multiflorum, scrophulariae, salviae miltiorrhizae, red peony roots, raw hawthorns, rhizoma chuanxiong, cassia twig, raw fossil fragments, raw oyster shells, earthworms, amomum, rhizoma alismatis, astragalus, ephedra, radix glycyrrhizae, pulp of cornus and the like. The traditional Chinese medicine composition integrates tonifying and dredging and has the effects on promoting blood circulation and removing blood stasis, promoting circulation of qi and blood, enhancing metabolism and repairing important viscera trauma, and promoting metabolism and regeneration of brain cells, liver cells and myocardial cells. Heart system diseases comprise tachycardia, bradycardia, premature beat, atrial fibrillation and flutter, atrioventricular block, branch conduction block, sick sinus syndrome, pre-excitation syndrome, heart failure, carditis, pericarditis, part of neurosis and the like. The tradition Chinese medicine composition has the miracle effect on treating stagnation of the heart-blood, chest obstructions and chest pains and has the good curative effects on repairing rheumatic heart disease cardiac muscle valves and treating congenital heart disease valve defects and cardiac muscle inferior myocardial infarction.

The invention discloses a self-synchronizing wireless heart pacemaker and a stimulating method thereof. The system is provided with a mechanical sensing detecting module, a pacemaker module, a processing module and a power supplying module, the primary function of the pacemaker is to sense and make pace of the heart of a patient, the contraction force of cardiac muscle cells of the heart can be sensed through the mechanical sensor, so that the purpose of the synchronous sensing of the beat of atrium cordis and ventricle using a pacemaker without a guiding wire is achieved to determine the cardiac cycle, the transmitting of a pace-making impulse is regulated by a pace-making regulating system according to sensed signals, and therefore the problem of the failure of making atrioventricular synchronous pace caused by atrioventricular block can be prevented.

The invention relates to atrioventricular block detection method, apparatus and electronic equipment base on electrocardiograph signals. The atrioventricular block detection method comprises the following steps: extracting signal waveform from an electrocardiograph signal; acquiring an atrioventricular block characteristic of the signal waveform, wherein the atrioventricular block characteristic is any one selected from correlation value of power spectral density, PR interval duration and a PR interval variation parameter; inputting the atrioventricular block characteristic into a detector; and then, acquiring detection result outputted by the detector so as to obtain the signal type of the electrocardiograph signal, wherein the detection result is a result detected by the detector according to the atrioventricular block characteristic, and the signal type include atrioventricular block and non-atrioventricular block. Being adopted, the atrioventricular block detection method is capable of more accurately identifying atrioventricular block so as to avoid the condition that non-atrioventricular block is wrongly identified as atrioventricular block due to individual differences; andthus, accuracy of atrioventricular block detection is improved.

The present invention relates to NKX2-5 gene mutation of atrial septal defect and its detection method. The NKX2-5 gene mutation is intron +1433.C-->T mutation, and has genetic coseparation to familial atrial septal defect and atrioventricular block (FASDAVB). Its detection method includes the following steps: 1. extracting peripheral blood DNA; 2. in vitro PCR amplification of NKX2-5 gene; and 3. DNA sequencing analysis. The discovery of the NKX2-5 gene mutation can define the molecular genetic mechanism of FASDAVB further.

An implantable medical device and a method for operating such a device to provide cardiac pacing to the heart of a patient for pacing hearts of patients suffering from periodical or intermittent atrio-ventricular blocks, for example, AV block or HIS block. A control circuit operates the device in a DDI-II mode, the DDI-II mode being an operation mode with an atrial inhibited pacing and a DDI-II mode ventricular pacing rate being lower than a predetermined base rate of a pulse circuit of the device, during periods with atrio-ventricular conduction conditions. If a block in atrio-ventricular conduction is detected and at least one first switching criterion is satisfied, the control circuit causes a switching circuit to switch from the DDI-II mode to the DDI mode and, if a block in atrio-ventricular conduction is detected and at least one second switching criterion is satisfied, the control circuit causes the switching circuit to switch from the DDI mode to the DDD mode. The control circuit is adapted to control the switching circuit to switch back to the DDI-II mode at satisfaction of a reinitiating criterion.

The invention provides a cardiac pace making system which comprises a perception module, a pace making module and a control module. Under a normal atrioventricular conduction condition, the control module controls the cardiac pace making system to work in a first mode and detect whether atrioventricular block occurs; various atrioventricular block events can be judged accurately by sensing and comparing PR (punctum remotum) intervals and ventricular event missing; when the atrioventricular block occurs, the control module controls the cardiac pace making system to work in a second mode; and acardiac pacemaker can timely work in an appropriate mode and provide an appropriate AV (atrioventricular) time sequence and a ventricular rhythm.

Mice homozygous for the lack of inward-rectifying potassium channel Kir6.1 gene are disclosed. The mice causes a high incidence of sudden death associated with arrhythmia (atrioventricular block) caused by spontaneous cardiac ischemia, a condition similar to Prinzmetal angina (variant angina) in human, representing an animal model of Prinzmetal angina. Mice heterozygous for the lack of inward-rectifying potassium channel Kir6.1 gene are also disclosed, which are used as parent mice for reproduction of the homozygous mice.

The invention relates to the technical field of bioengineering. At present, many problems and difficulties exist in treating atrioventricular block through gene transfection and cell transplantation, and the current situation of researchment of biological pacing therapy is considered, so that a method that a tissue engineering conduction bundle is constructed in vitro by utilizing conduction bundle cells and scaffold materials so as to be transplanted to heart for repairing or reconstructing heart conduction path is an ideal solution of atrioventricular block therapy subject. However, no researchment of construction of the tissue engineering conduction bundle is reported at home and abroad. The invention aims to provide the tissue engineering conduction bundle and a construction method thereof. The construction method is characterized in that: heart conduction cells obtained by inducing collagen sponge and marrow mesenchymal stem cells are utilized to construct the tissue engineering conduction bundle. The tissue engineering conduction bundle provided by the invention has the characteristic of electrocardio conduction, can be used for treatment of transplant, and brings hope to treatment of arrhythmia diseases caused by atrioventricular block.

The invention discloses a Chinese medicinal preparation for treating atrioventricular conduction block, which is prepared from the following raw materials in part by weight: 35 to 85 parts of luvunga, 30 to 80 parts of obscured homalomena rhizome, 25 to 75 parts of pilose asiabell root, 20 to 70 parts of danshen root, 10 to 40 parts of turmeric root-tuber, 15 to 60 parts of nutgrass galingale rhizome, 15 to 60 parts of red paeony root and 25 to 70 parts of Indian buead. The Chinese medicinal preparation for treating the atrioventricular conduction block has the effects of soothing sinews and quickening network vessels, freeing heart yang, quickening blood and dispelling stasis, supplementing center and boosting vital energy, moving vital energy and resolving depression, coursing liver vital energy, moving depression and eliminating stagnation, benefiting spleen and stomach, quieting heart and soothing nerves. The Chinese medicinal preparation is unique in medication and reasonable in medicament property, and has obvious curative effect of preventing and curing the atrioventricular conduction block. The Chinese medicinal preparation is the pure Chinese medicinal preparation without damage to liver and kidney.

A zero flow responsive heart stimulator contains a zero flow sensors, which generate signals at the moment of the termination of blood inflow in the right atrium and the right ventricle, sensing this the most precisely in the places, where the sinoatrial node and atrioventricular node reside, for the right atrium and the right ventricle, respectively. The stimulator is based on our discovery, that the two nodes are the same sensors in the biological systems, based on the fact that until the filling of the said two chambers continues, the venous blood flow sucks on Bernoulli's principle the Ca and Na cations from the two nodes interstices, preventing the inward currant in their cells, thus delaying the completion of the 0-phase of their depolarization and the action potential, until the blood flow stops. Our discovery proves that the alternating flow / no flow of the blood in the orifice of superior vena cava and the entrance of the right ventricle is the real pacemaker that fires the both nodes, but not the inverse, as generally assumed, approximating the natural pacemaker to a clock mechanism. This, together with the discovered by us arteriovenous, arteriolymphatic and capillary pumps, closes the loop of the autonomous automatic functioning of the cardiovascular system, even completely denervated and in the absence of muscle contractions. It is the first devise, which activates the atrial and the ventricular contractions in a function of the zero-flow of the filling them venous blood, which is the exact imitation of the sinoatrial and atrioventricular firing.

The present invention provides a use of a traditional Chinese drug composition in preparing a drug for treating atrioventricular block. The traditional Chinese drug composition comprises the following traditional Chinese drugs: ginseng, creeping liriope, dogwood, dan-shen root, fried spine date seed, Chinese taxillus herb, red peony, ground beetle, Chinese nardostachys root and rhizome, and the like. The results of clinical experiments show that: the traditional Chinese drug composition provides a significant clinical effect for treatment of the atrioventricular block.

The invention relates to the technical field of medicine, in particular to the application of tamoxifen in the preparation of medicines for preventing and treating cardiotoxic side effects caused by bupivacaine. The drug can effectively prevent and treat cardiac toxic side effects such as bradycardia, atrioventricular or intraventricular conduction block, and ventricular arrhythmia caused by bupivacaine.

The invention discloses a traditional Chinese medicine for treating congestive heart failure. The medicament is prepared from the following components: 8 to 15 parts by weight of radix astragali, 8 to 15 parts by weight of salvia miltiorrhiza, 2 to 6 parts by weight of prepared common monkshood daughter root, 8 to 15 parts by weight of epimedium, 2 to 6 parts by weight of ginseng, 8 to 12 parts by weight of Chinese angelica, 8 to 12 parts by weight of szechuan lovage rhizome, 8 to 12 parts by weight of ganoderma and 8 to 12 parts by weight of immature bitter orange. The invention also discloses a preparation process of the traditional Chinese medicine for treating congestive heart failure. The traditional Chinese medicine is developed on the basis that an applicant deeply understands symptoms and pathological mechanisms of congestive heart failure. The traditional Chinese medicine has the advantages of reasonable prescription, significant curative effect and strong applicability. According to statistics, after a course of treatment, the traditional Chinese medicine is effective in 24 cases out of 28 cases and ineffective in 4 cases out of 28 cases of patients with cardiac function diseases class II, and the traditional Chinese medicine is effective in 2 cases out of 3 cases and ineffective in 1 of 3 cases of patients with cardiac function diseases class III,. The effective rate is 83.9 percent. In 4 cases out of 6 cases, the cardiac rate of patients with bradycardia is improved to different extent; in 3 cases out of 4 cases, patients with atrioventricular block class I recover to a normal level during P-R; and the phenomenon of aggravating atrioventricular block does not occur in the course of treatment. All patients have no obvious adverse reaction.

A method of creating an atrioventricular bypass tract for a heart comprises growing mesenchymal stem cells into a strip with two ends, attaching one end of the strip onto the atrium of the heart, and attaching the other end of the strip to the ventricle of the heart, to create a tract connecting the atrium to the ventricle to provide a path for electrical signals generated by the sinus node to propagate across the tract and excite the ventricle.

The invention relates to an application of swertianolin (chemical name is 1,5,8-trihydroxy-3-methoxy xanthone-8-oxy glucoside, swertianolin) shown as a formula (I) and extract thereof in preparation of a medicine used for preventing and treating arrhythmia. The invention also discloses a pharmaceutical composition containing the swertianolin or a pharmaceutically acceptable carrier, excipient or diluter thereof as an active ingredient. Pharmacological experimental study results show that a swertianolin compound and an extract thereof have an antiarrhythmic effect, can obviously reduce atrioventricular block and ventricular tachycardia which are caused by aconitine and can reduce activity of blood serum myocardial enzyme during arrhythmia; and the swertianolin compound has similar pharmacological properties compared with a positive control lidocaine group. The study results of the invention provide powerful scientific basis for rational utilization of gentianella acuta Chinese herbal medicine.

The invention relates to the technical field of bioengineering. At present, many problems and difficulties exist in treating atrioventricular block through gene transfection and cell transplantation, and the current situation of researchment of biological pacing therapy is considered, so that a method that a tissue engineering conduction bundle is constructed in vitro by utilizing conduction bundle cells and scaffold materials so as to be transplanted to heart for repairing or reconstructing heart conduction path is an ideal solution of atrioventricular block therapy subject. However, no researchment of construction of the tissue engineering conduction bundle is reported at home and abroad. The invention aims to provide the tissue engineering conduction bundle and a construction method thereof. The construction method is characterized in that: heart conduction cells obtained by inducing collagen sponge and marrow mesenchymal stem cells are utilized to construct the tissue engineering conduction bundle. The tissue engineering conduction bundle provided by the invention has the characteristic of electrocardio conduction, can be used for treatment of transplant, and brings hope to treatment of arrhythmia diseases caused by atrioventricular block.

The invention relates to traditional Chinese medicine for treating atrioventricular block. The traditional Chinese medicine is prepared from the following raw pharmaceutical materials in parts by weight: 15 parts of fructus trichosanthis, 10 parts of bulbus allii macrostemi, 10 parts of salvia miltiorrhiza, 2 parts of alpine oak leaf extract, 12 parts of matricaria chamomilla, 25 parts of abutilon indicum, 15 parts of crepis phoenix dunn, 12 parts of cyperus malaccensis and 8 parts of phlomis tuberosa. Proved by clinical trials, the traditional Chinese medicine can be used for safely and effectively treating atrioventricular block.

A method for allowing an animal to develop atrioventricular block, the method including: administering an immune regulator targeting a sphingosine-1-phosphate receptor to an animal selected from a pig, a monkey and a guinea pig.